This is a prospective, parallel group, randomized, investigator-blinded pilot study.
Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a
weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study
is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators
will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record
adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life
Quality Index.)